OnePin Peptide Library · Weight
Adipotide
FTPP · Fat-Targeted Proapoptotic Peptide · CKGGRAKDC-KLAKLAK
Adipotide is a synthetic targeting peptide consisting of a homing motif (CKGGRAKDC, which binds prohibitin on white adipose tissue vasculature) fused to a pro-apoptotic domain (D(KLAKLAK)2). Designed to selectively destroy the blood vessels supplying white fat depots, causing rapid fat loss in obese primates without significantly affecting other organs in preclinical studies. Phase 1 trials in obese humans were initiated but limited by dose-dependent renal toxicity. Not FDA-approved; remains an experimental research chemical with significant safety concerns.
Daily for 28 days per published clinical schedule. NOT a chronic-use peptide. Renal monitoring (creatinine, BUN, urine protein) recommended throughout cycle and post-cycle.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Adipotide combines two functional domains:
Targeting Domain (CKGGRAKDC)
Binds prohibitin, a protein highly expressed on white adipose tissue vasculature endothelial cells. This provides selectivity for white fat depots over other tissues.
Pro-Apoptotic Domain (D(KLAKLAK)2)
A synthetic peptide that disrupts mitochondrial membranes upon internalization, triggering apoptosis in cells where it accumulates.
Net Effect
Selective destruction of white adipose vasculature → ischemic apoptosis of underlying adipocytes → rapid fat loss. In obese primate studies, treatment produced 11% weight loss over 4 weeks with preserved lean mass.
Toxicity Mechanism
Phase 1 trials in obese men (Barnhart et al. 2014) showed dose-dependent nephrotoxicity (elevated creatinine, proteinuria) - thought to reflect renal accumulation and/or off-target prohibitin binding in the kidney. This limited dose escalation and ultimately the program's clinical viability.
What to expect
Week 1-2: subtle effects; renal monitoring starts.
Week 2-4: peak fat loss in primate models; renal signal may emerge.
Post-cycle: 4-week observation with renal labs.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Keep separate
Side effects & safety
Commonly reported
- Injection site reactions
- Possible mild nausea
- Renal effects (creatinine elevation, proteinuria) - DOSE LIMITING
Less common & notes
- Acute kidney injury at higher doses.
- Hypotension.
- Long-term safety completely uncharacterized.
- The renal toxicity signal in Phase 1 is the primary safety concern and the reason this compound did not advance further in clinical development.
- Off-label community use is high-risk.
Pharmacokinetics
Storage. Lyophilized: refrigerate or freeze. Reconstituted: refrigerate, use within 14 days. Cytotoxic peptide - careful handling.
Regulatory status
Not FDA-approved. Phase 1 trials limited by renal toxicity. Sold only as research chemical. WADA prohibited.
Put it to work
Calculate, log & track
Open Adipotide straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Adipotide in the app →Go deeper
The guide & community
The complete Adipotide walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗